NCT05788107
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2023); last known: Not Yet Recruiting
- Notable Primary completion date: May 2024 to May 2025
- Start date: Jun 2023 to Jun 2024
- Study completion date: Oct 2024 to Oct 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The Dose-Limiting Toxicity (DLT) of HLX51 within 3 weeks after the first Administration
Timeframe: At the end of Cycle 1 (each cycle is 21 days)
The maximum tolerated dose (MTD) of HLX51 within 3 weeks after the first administration
Timeframe: At the end of Cycle 1 (each cycle is 21 days)
Arms and interventions
HLX51 GroupExperimental
The initial dose of HLX51 is 0.3mg/kg, and 5 dose levels are designed: 0.3 mg/kg, 1 mg/kg , 2.5mg/kg, 5mg/kg, and 10mg/kg (Q3W). Patients with good tolerability and well controlled disease will receive the treatment until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
Drugs: HLX51